Pomerantz says it filed class action over Regeneron Fianlimab disclosures
Pomerantz LLP said it filed a class action against Regeneron Pharmaceuticals over disclosures about its Phase III Fianlimab-Libtayo study and related stock drops.
Pomerantz LLP says investors who bought Regeneron securities during the class period may seek lead-plaintiff status in a class action tied to company disclosures about a Phase III Fianlimab-Libtayo study.
Pomerantz LLP said in an Aug. 13 investor alert that it has filed a class action against Regeneron Pharmaceuticals Inc. The notice says the case concerns possible securities fraud or other unlawful business practices. It also says investors who purchased or otherwise acquired Regeneron securities during the class period have until Sept. 14, 2026, to ask the court to appoint them lead plaintiff.
The alert points to two company disclosures and the stock moves that followed. According to the notice, Regeneron said on April 29, 2026, during its first-quarter earnings call, that the Phase III Fianlimab-Libtayo study had been altered to expand the number of patients eligible for analysis of progression-free survival. The alert says the stock fell $45.41, or 6.21%, to close at $686.36 that day.
Pomerantz also cited a May 15, 2026, press release in which Regeneron said the Phase 3 trial of Fianlimab did not reach statistical significance for the primary endpoint of improvement in progression-free survival, or PFS. The alert says the stock fell $68.57, or 9.82%, to close at $629.68 on May 16, 2026.
Class-action notices like this one are designed to tell investors about litigation deadlines and the steps needed to take part in the case. The alert identifies Regeneron as trading on Nasdaq under the symbol REGN and says the complaint can be obtained on Pomerantz’s website.
The notice asks investors who want to seek lead-plaintiff status to contact Danielle Peyton at Pomerantz by email or phone. It says email inquiries should include a mailing address, telephone number and the number of shares purchased.
Pomerantz’s alert also includes a short firm profile, saying the firm has offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv. It describes Pomerantz as a pioneer in securities class actions.
The notice gives investors until Sept. 14 to ask the court to appoint a lead plaintiff.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()